Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lilly

The ‘next Ozempic’ became a social media sensation. Then everything changed

When Mounjaro came on the market, TikTok went wild. People with obesity ordered the drug in droves thanks to a coupon that allowed them to access it for just $25 a month. Then the coupon went away, leaving destruction in its wake — and obese patients warring with diabetics. Emily…

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

The 5 Safest Stocks You Can Buy in 2023

The stock market might remain volatile in the near term amid the still-alarmingly high inflation and the anticipated continuation of rate hikes. Therefore, fundamentally strong Eli Lilly (LLY), Novartis (NVS), Comcast (CMCSA), HCA Healthcare (HCA), and Myers Industries (MYE), which pay steady dividends, might be safe buys now. Read more.

StockNews.com

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent UK

Lilly shares slip as FDA seeks more Alzheimer's drug data

Eli Lilly shares slipped Friday morning after regulators said they need to see more data on the company’s application for a quick approval of its potential Alzheimer’s disease treatment

The Independent UK

Obesity treatments catch drugmakers’ eyes as sales seen soaring

Three years ago, drugmakers and laboratories around the world responded to the pandemic with Covid-19 vaccines. Now that the urgency has faded, they’re collectively turning attention to an older pandemic: obesity.

Tribune News Service

A TikTok trend sold out Ozempic, leaving people with diabetes dizzy, scared

For more than a month, Shane Anthony, a 57-year-old auto mechanic, hasn’t been able to get his diabetes medication.

Tribune News Service

3 Large-Cap Stocks to Add to Your Portfolio Now

The Fed’s aggressive stance on inflation has weighed heavily on the stock market this year. As large-cap stocks usually can weather challenging economic conditions, sound large-cap stocks Eli Lilly (LLY), Agilent Technologies (A), and Fortinet (FTNT) might be wise additions to your portfolio. Keep reading.

StockNews.com

Pharmaceutical giant Eli Lilly & Co apologises after fake Twitter account says insulin is free as Elon Musk rolls back verification

The incident is among a wave of impersonations that prompted Twitter to make its relaunched premium service unavailable.

ABC News

No, insulin is not free: Eli Lilly is the latest high-profile casualty of Elon Musk’s Twitter verification mess

Eli Lilly shares fell after pranksters using Twitter Blue impersonated it and made a surprising claim—and this might be just the beginning.

Fortune

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Pharmaceutical companies’ stocks dive after verified imposter Twitter account claims ‘insulin is free’

Insulin producers Eli Lilly, Novo Nordisk and Sanofi all reported losses during Friday’s trading

The Guardian - US

These companies claim to support abortion rights. They are backing anti-abortion Republicans

An analysis of major companies’ donations, including Meta and Amazon, reveals donations to candidates calling for banning the procedure

Tribune News Service

New generation of weight loss medications offer promise — but at a price

Excitement is building about a new generation of drugs that tout the ability to help adults with excess weight shed more pounds than older drugs on the market.

StockNews.com

3 Names It Wouldn’t Hurt to Stock up On

Despite the Fed’s continued hawkish stance, the September inflation report came in hotter than expected, raising the possibility of another aggressive interest rate hike in November. However, it could be smart to keep investing in quality stocks to benefit from their rebound. We think Microsoft (MSFT), Eli Lilly (LLY), and…

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Elon Musk Twitter Case Deposition Delayed, FTX US Goes Shopping, Spotify's Analyst Sees Audiobooks Immaterial: Top Financial Media Stories Tuesday, Sept. 27

Bloomberg

Chicago Sun-Times

Another reason not to work in Indiana

Eli Lilly and Co. was quick to understand just how bad a near abortion ban can be on business.

Tribune News Service

Eli Lilly says Indiana abortion law forces hiring out-of-state

Eli Lilly & Co., one of Indiana’s largest employers, said the state’s freshly passed restrictions on abortion would force the drugmaker to “plan for more employment growth outside our home state.”

The Independent UK

Major Indiana employer speaks out on state’s near-total abortion ban and vows to look outside state for ‘employment growth’

Pharmaceutical giant Eli Lilly is headquartered in Indianapolis and employs more than 10,000 people in the state

Daily Mirror

Kerry Katona wants daughter Lily, 19, to have baby as she's worried about dying

Kerry says her “health anxiety” causes her to constantly worry about dying young and she would love for her teenage daughter Lilly to have a child of her own

Los Angeles Times

Michael Hiltzik: As professionals flee antiabortion policies, red states face a brain drain

A few days ago, a university headhunter reached out to Elizabeth T. Jacobs, a professor of epidemiology at the University of Arizona, to gauge her interest in moving to a leading university in Texas.

Benzinga

Sanofi Lowers Out-Of-Pocket Insulin Cost For Uninsured Patients

Sanofi SA (NASDAQ:SNY) said that uninsured diabetes patients in the U.S. will pay no more than $35 for a 30-day supply of insulin, down from $99. Sanofi said the new price would be effective from July 1. The announcement from Sanofi follows House passage (232-193) of the monthly cap in March, with just 12…

1 … 13 14 15 16

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations